Literature DB >> 16635045

A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists.

I R Bruns1, S Chhum, A T Dinh, H Doerr, N R Dunn, Y T Ly, C L Mitman, H D Rickards, C Sol, E W Wan, R B Raffa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16635045     DOI： 10.1111/j.1365-2710.2006.00714.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN： 0269-4727            Impact factor:   2.512


× No keyword cloud information.
  3 in total

1.  CARMA3: A novel scaffold protein in regulation of NF-κB activation and diseases.

Authors:  Jiyuan Sun
Journal:  World J Biol Chem       Date:  2010-12-26

2.  An opioid agonist that does not induce mu-opioid receptor--arrestin interactions or receptor internalization.

Authors:  C E Groer; K Tidgewell; R A Moyer; W W Harding; R B Rothman; T E Prisinzano; L M Bohn
Journal:  Mol Pharmacol       Date:  2006-11-07       Impact factor: 4.436

Review 3.  β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders.

Authors:  Jaana van Gastel; Jhana O Hendrickx; Hanne Leysen; Paula Santos-Otte; Louis M Luttrell; Bronwen Martin; Stuart Maudsley
Journal:  Front Pharmacol       Date:  2018-11-28       Impact factor: 5.810
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.